Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma

Chalaye, Julia; Costentin, Charlotte; Luciani, Alain; Amaddeo, Giuliana; Ganne-Carrié, Nathalie; Baranès, Laurence; Allaire, Manon; Caldéraro, Julien; Azoulay, Daniel; Nahon, Pierre; Séror, Olivier; Mallat, Ariane; Soussan, Michaël; Duvoux, Christophe; Itti, Emmanuel; Nault, Jean–Charles

doi:10.1016/j.jhep.2018.02.018

Cited by 49 publications

(70 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The extrahepatic HCC foci were located in bone (n = 5 foci), lung tissue (n = 2 foci) and lung vessels (n = 1 foci) ( Figure 4 shows an example). 18 F-FDG PET/CT did not reveal any extrahepatic HCC not detected by 18 F-FDGal PET/CT. 18 F-FDG PET/CT detected four extrahepatic foci that were not HCC and not detected by 18 F-FDGal PET/CT.…”

Section: Extrahepatic Findingsmentioning

confidence: 66%

“…Median time between 18 F-FDGal PET/CT and biochemistry was 5 days (range, 0-31 days). Missing data are not included.…”

Section: Discussionmentioning

confidence: 99%

“…The eight extrahepatic HCC foci (in six patients) were all detected by 18 F-FDGal PET/CT. Six of these foci (in five patients)…”

Section: Extrahepatic Findingsmentioning

confidence: 98%

“…Fifty patients were thus included in the final analysis. When possible, with regards to the fast-track treatment plan, 18 F-FDG PET/CT was also performed before treatment (n = 29 patients).…”

Section: Study Population and Designmentioning

confidence: 99%

“…Fifty patients were examined and in five patients (10%), 18 For assessment of sensitivity, all scans were anonymized and re-evaluated after a washout period of at least four weeks to avoid reading-order effects. This time, the readers (SMK (nuclear medicine physician) and SS (radiologist)) had access only to the ceCT without potential bias from the abovementioned additional information.…”

Section: Key Pointsmentioning

confidence: 99%

See 4 more Smart Citations

[¹⁸F]‐Fluoro‐2‐deoxy‐D‐galactose positron emission tomography/computed tomography as complementary imaging tool in patients with hepatocellular carcinoma

Bak-Fredslund

Keiding

Villadsen

et al. 2019

Liver International

View full text Add to dashboard Cite

Background & Aims: Positron emission tomography (PET) with the liver-specific tracer [ 18 F]-fluoro-2-deoxy-D-galactose ( 18 F-FDGal) can be used for imaging of hepatocellular carcinoma (HCC). Curative intended and locoregional treatments of HCC require absence of extrahepatic disease. The aim of this prospective study was to determine whether adding 18 F-FDGal PET/CT to standard work-up changes the planned treatment in patients with HCC deemed suitable for curative or locoregional treatment. Methods: Fifty patients with HCC were included at our tertiary liver centre. The primary study outcome was a change in treatment strategy. A subgroup of 29 patients was also examined with [ 18 F]-fluoro-2-deoxy-D-glucose ( 18 F-FDG) PET/CT for comparison.Results: 18 F-FDGal PET/CT detected eight extrahepatic HCC metastases in six patients (12%), which were primarily not detected by ceCT or MRI. These findings led to a change in treatment in five patients (10%). One of the eight extrahepatic HCC foci was also detected by 18 F-FDG PET/CT. A total of 85 malignant intrahepatic foci were examined, 12 of these were new findings by 18 F-FDGal PET/CT which had a sensitivity of 71%, highest for large foci. None of the additional intrahepatic foci found by 18 F-FDGal PET changed the planned treatment. Conclusions:For the detection of extrahepatic HCC metastases, 18 F-FDGal PET/CT was superior both to standard clinical work-up with contrast-enhanced CT, and/or MRI, and to 18 F-FDG PET/CT in patients deemed suitable for locoregional treatment. 18 F-FDGal PET/CT led to a change in the planned treatment in 10% of the patients whereas 18 F-FDG PET/CT did not change the planned treatment in any patient.

show abstract

Section: Extrahepatic Findingsmentioning

confidence: 66%

“…Median time between 18 F-FDGal PET/CT and biochemistry was 5 days (range, 0-31 days). Missing data are not included.…”

Section: Discussionmentioning

confidence: 99%

“…The eight extrahepatic HCC foci (in six patients) were all detected by 18 F-FDGal PET/CT. Six of these foci (in five patients)…”

Section: Extrahepatic Findingsmentioning

confidence: 98%

Section: Study Population and Designmentioning

confidence: 99%

Section: Key Pointsmentioning

confidence: 99%

See 3 more Smart Citations

[¹⁸F]‐Fluoro‐2‐deoxy‐D‐galactose positron emission tomography/computed tomography as complementary imaging tool in patients with hepatocellular carcinoma

Bak-Fredslund

Keiding

Villadsen

et al. 2019

Liver International

View full text Add to dashboard Cite

show abstract

A pH‐Responsive Glycyrrhetinic‐Acid‐Modified Small‐Molecule Conjugate for NIR Imaging of Hepatocellular Carcinoma (HCC)

et al. 2019

View full text Add to dashboard Cite

We report a glycyrrhetinic‐acid (GA)‐decorated small‐molecule conjugate for pH‐triggered near‐infrared (NIR) fluorescence imaging of hepatocellular carcinoma (HCC). Our in vitro studies demonstrated that the conjugate, referred to as NIR‐GA, was efficiently taken up by liver cancer cell lines such as HepG2 and Huh7 through an endocytic pathway mediated by GA receptors. As suggested by co‐localization studies, NIR‐GA mainly localized in the lysosome, where the acidic pH results in the activation of the fluorescent dye through H+‐triggered spirolactam ring opening to give strong fluorescence in the NIR region.

show abstract

Addition of [18F]Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography to Cross‐Sectional Imaging Improves Staging and Alters Management in Hepatocellular Carcinoma

et al. 2020

View full text Add to dashboard Cite

In this work, we characterize the value of positron emission tomography (PET) with computed tomography (CT) in combination with cross-sectional imaging for staging and prognostication of hepatocellular carcinoma (HCC) patients. In this retrospective cohort study, HCC patients underwent PET-CT after initial staging with contrast-enhanced CT or magnetic resonance imaging (MRI). The benefit of PET-CT was measured by the identification of new HCC lesions, and potential harm was quantified by the number of false positives and subsequent diagnostic evaluation. We used multivariate Cox regression analysis to evaluate the association between the highest grade on PET-CT with the risk of extrahepatic metastasis, progression-free, and overall survival. Among 148 patients, PET-CT detected additional extrahepatic metastasis in 11.9% of treatment-naïve and 13.8% of treatmentexperienced patients. PET-CT changed the Barcelona Clinic Liver Cancer (BCLC) staging in 5.9% of treatment-naïve and 18.8% of treatment-experienced patients compared with CT/MRI alone, changing HCC management in 9.9% and 21.3% of patients, respectively. Of the patients, 5% (n = 8) experienced severe physical harm requiring additional procedures to evaluate extrahepatic findings. High tumor grade on PET-CT was independently associated with a higher likelihood of extrahepatic metastasis (hazard ratio [HR], 17.1; 95% confidence interval [CI], 3.6-81.5) and worse overall survival (HR, 2.4; 95% CI, 1.4-4.3). Treatment-experienced patients (versus treatment-naïve patients; HR, 9.7; 95% CI, 1.9-49.4) and BCLC stage A (HR, 8.2; 95% CI, 1.5-45.9; P < 0.01) and BCLC stage B (HR, 20.6; 95% CI, 1.5-282.2; P < 0.05) were more likely to have an upstaging with PET-CT compared with BCLC stage C (reference). PET-CT provides prognostic information and improves tumor staging beyond CT/MRI alone, with subsequent changes in management for patients with HCC.Liver Transplantation 26 774-784 2020 AASLD.

show abstract

Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma

Cited by 49 publications

References 20 publications

[¹⁸F]‐Fluoro‐2‐deoxy‐D‐galactose positron emission tomography/computed tomography as complementary imaging tool in patients with hepatocellular carcinoma

[¹⁸F]‐Fluoro‐2‐deoxy‐D‐galactose positron emission tomography/computed tomography as complementary imaging tool in patients with hepatocellular carcinoma

A pH‐Responsive Glycyrrhetinic‐Acid‐Modified Small‐Molecule Conjugate for NIR Imaging of Hepatocellular Carcinoma (HCC)

Addition of [18F]Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography to Cross‐Sectional Imaging Improves Staging and Alters Management in Hepatocellular Carcinoma

Contact Info

Product

Resources

About

Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma

Cited by 49 publications

References 20 publications

[18F]‐Fluoro‐2‐deoxy‐D‐galactose positron emission tomography/computed tomography as complementary imaging tool in patients with hepatocellular carcinoma

[18F]‐Fluoro‐2‐deoxy‐D‐galactose positron emission tomography/computed tomography as complementary imaging tool in patients with hepatocellular carcinoma

A pH‐Responsive Glycyrrhetinic‐Acid‐Modified Small‐Molecule Conjugate for NIR Imaging of Hepatocellular Carcinoma (HCC)

Addition of [18F]Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography to Cross‐Sectional Imaging Improves Staging and Alters Management in Hepatocellular Carcinoma

Contact Info

Product

Resources

About

[¹⁸F]‐Fluoro‐2‐deoxy‐D‐galactose positron emission tomography/computed tomography as complementary imaging tool in patients with hepatocellular carcinoma

[¹⁸F]‐Fluoro‐2‐deoxy‐D‐galactose positron emission tomography/computed tomography as complementary imaging tool in patients with hepatocellular carcinoma